Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical-Lingual Semaglutide in Adults With Obesity
NCT07728383Phase 4Recruiting
- Sponsor
- Gila Therapeutics
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Gila Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07728383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728383.